apixaban viatris 5 mg apvalkotās tabletes
viatris limited, ireland - apiksabāns - apvalkotā tablete - 5 mg
dabigatran etexilate viatris 110 mg cietās kapsulas
viatris limited, ireland - dabigatrāna eteksilāts - kapsula, cietā - 110 mg
pazopanib viatris 200 mg apvalkotās tabletes
viatris limited, ireland - pazopanibs - apvalkotā tablete - 200 mg
pazopanib viatris 400 mg apvalkotās tabletes
viatris limited, ireland - pazopanibs - apvalkotā tablete - 400 mg
abacavir/lamivudine viatris 600 mg/300 mg apvalkotās tabletes
viatris limited, ireland - abacavirum, lamivudinum - apvalkotā tablete - 600 mg/300 mg
bisacodyl viatris 5 mg apvalkotās tabletes
viatris healthcare limited, ireland - bisakodils - apvalkotā tablete - 5 mg
dutasteride/tamsulosin viatris 0,5 mg/0,4 mg cietās kapsulas
viatris limited, ireland - dutasteridum, tamsulosini hydrochloridum - kapsula, cietā - 0,5 mg/0,4 mg
rivaroxaban viatris (previously rivaroxaban mylan)
mylan ireland limited - rivaroxaban - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - antitrombotiskie līdzekļi - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers. rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery. treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.
hartil 10 mg tabletes
egis pharmaceuticals plc, hungary - ramiprils - tablete - 10 mg
hartil 2,5 mg tabletes
egis pharmaceuticals plc, hungary - ramiprils - tablete - 2,5 mg